Humira Biosimilar Drug Accepted to Conduct Clinical Trial in UK for Crohn’s, Other Autoimmune Diseases

Humira Biosimilar Drug Accepted to Conduct Clinical Trial in UK for Crohn’s, Other Autoimmune Diseases
Cambridge, Massachusetts-based biotechnology company, Momenta Pharmaceuticals, Inc., has just announced the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the company’s Clinical Trial Application (CTA) for a study of M923, a biologic similar to TNF inhibiting anti-inflammatory drug Humira® (adalimumab) by AbbVie, Inc., for the management of inflammatory processes associated with autoimmune diseases such

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *